Collaborative R&D and licensing agreement for Stapled Peptide Therapeutics

Roche
Aileron Therapeutics

Aug 24 2010
Collaborative R&D and licensing agreement for Stapled Peptide Therapeutics

Companies: Roche  
Aileron Therapeutics
Announcement date: Aug 24 2010
Deal value, US$m: 1125.0 : sum of upfront and milestone payments

Details

- Announcement date: Aug 24 2010
- Industry sectors: Bigpharma, Pharmaceutical, Biotech, Research tools, Central Nervous System
- Therapy areas: Immunology » Inflammation, Oncology, Peptides
- Technology types: Proteomics, Small molecules
- Deal components: Collaborative R&D, Licensing
- Stages of development: Discovery

Financials

- Deal value, US$m: 1125.0 : sum of upfront and milestone payments
- Upfront, US$m: 25.0 : upfront payment
- Milestones, US$m: 1100.0 : dependent on discovery, development, regulatory and commercial milestones
- Funding, US$m: n/d : R&D funding

Termsheet

16 November 2011
Roche will initiate a new program to expand its collaboration with Aileron to discover, develop and commercialize Stapled Peptide drugs.

Aileron and Roche will now commence work on a third program focused on inflammatory diseases.

24 August 2010
Aileron Therapeutics and Roche have a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics.

Roche will work with Aileron to develop drug candidates against up to five targets which include oncology, virology, inflammation, metabolism and CNS.

© 2009-2020, Wildwood Ventures Ltd. All rights reserved.
Roche will provide Aileron guaranteed funding of at least $25 million in technology access fees and R&D support.

Aileron is eligible to receive up to $1.1 billion in payments upon the achievement of discovery, development, regulatory and commercialisation milestones, if drug candidates are developed against all five targets.

Aileron will receive royalties on future sales for any marketed products that result from the collaboration.

Press Release

16 November 2011

Roche (RHHBY) and Aileron Therapeutics Expand Collaboration for Stapled Peptide Drugs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics announced today that Roche will initiate a new program to expand its collaboration with Aileron to discover, develop and commercialize Stapled Peptide drugs. The potential $1.1 billion drug development collaboration, launched in August 2010, encompassed up to five programs of strategic importance to Roche; initially Aileron launched the collaboration around two key programs in oncology. Pursuant to the expanding relationship, Aileron and Roche will now commence work on a third program focused on inflammatory diseases.

Aileron also announced that it achieved a key milestone under the collaboration agreement triggering a substantial milestone payment related to in vivo proof-of-concept against one of the programs of importance to Roche. Financial details of the agreement and milestone payment are not being disclosed.

"In our first program, this collaboration has already demonstrated in vivo proof-of-concept in multiple models, and shown novel mechanistic capabilities," said Jean-Jacques Garaud, global head of Roche Pharma Research and Early Development. "We now want to expand our work with Aileron and broaden the impact of Stapled Peptides in our portfolio to create drugs for disease targets that are intractable using currently available modalities."

“We have now demonstrated in conjunction with a world-class drug development partner that – as we expected – our Stapled Peptide drugs are capable of addressing targets, in manner and effect, that have eluded small molecules and antibodies,” stated Joseph A. Yanchik, III, president and CEO of Aileron. "Given the potential impact of this technology and the associated scrutiny, it was essential for us to set a high bar and show early success with a partnered drug discovery program. I also want to acknowledge the tremendous work done by the combined Aileron-Roche team over the last year to deliver this rapid progress and look forward to our efforts to bring these drugs to patients."

Yanchik added, “Independent of our agreement with Roche, Aileron is pursuing several programs designed to provide clear clinical proof-of-concept for Stapled Peptides drugs and a rapid path to market in areas with significant unmet needs, including infectious diseases and muscular degenerative diseases.”

About Aileron Therapeutics

Aileron Therapeutics is the world leader in stabilized peptides. The company has built a powerful drug discovery engine centered on the multiple chemical-linking technologies comprising the company’s proprietary Stapled Peptides platform. Aileron’s platform enables the company to create drugs for important diseases that are implicated by highly sought after biological targets not well served by current small molecule or antibody approaches. Aileron’s Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and the company is developing a portfolio of Stapled Peptide drugs for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases.

With an exceptional team of drug developers, company builders and scientists, and the support of leading venture capital firms and pharmaceutical venture investors, as well as a collaboration with Roche, Aileron is turning its vision for the future of medicine into a reality. For more information, please visit www.aileronrx.com.

24 August 2010

Roche and Aileron Enter Multi-target Alliance to Develop Stapled Peptide Drugs for Diseases across Multiple Therapeutic Areas

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics and Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche’s key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.

Stapled Peptide Therapeutics are a result of Aileron’s breakthrough peptide stabilization technology, and are a potential solution to drug as-yet intractable disease targets, including those originating from long sought-after intracellular protein-protein interactions.

© 2009-2020, Wildwood Ventures Ltd. All rights reserved.
Under the terms of the agreement, Roche will provide Aileron guaranteed funding of at least $25 million in technology access fees and R&D support. Aileron is eligible to receive up to $1.1 billion in payments upon the achievement of discovery, development, regulatory and commercialisation milestones, if drug candidates are developed against all five targets. In addition, Aileron will receive royalties on future sales for any marketed products that result from the collaboration. Aileron will have substantial responsibility in collaboration with Roche to develop drug candidates against the selected targets up to clinical development.

“Roche is dedicated to advancing innovative therapies, and Stapled Peptides represent a potentially transformative new technology to create drugs for important disease targets that are intractable to currently available modalities,” said Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development. “This collaboration with Aileron is a strategically important endeavour for advancing a novel approach to developing new medicines and will accelerate our progress toward our ultimate goal of bringing important new treatments to patients with unmet medical needs.”

“This alliance with Roche validates the broad potential of our Stapled Peptide platform across multiple therapeutic areas and classes of targets and also provides Aileron with capital to advance our platform and internal drug development pipeline,” said Joseph A. Yanchik, III, President and CEO of Aileron. “We took our time to carefully consider several opportunities for our first industry collaboration, and believe that Roche is an ideal partner for Aileron because of its history with peptide therapeutics and its commitment to tackling difficult disease targets.”

**About Stapled Peptides**

Aileron’s proprietary Stapled Peptide technology platform “locks” peptides into their biologically active shape, mimicking the structures found in nature. This process captures the best features of both small molecules and therapeutic proteins, ultimately endowing the peptide with unique and beneficial drug-like properties, including efficient cell penetration, improved pharmacokinetics, high-affinity binding to large target protein surfaces and excellent stability within the body. This unique combination of features could greatly expand the number of “druggable” therapeutic targets, by providing a unique opportunity to address the thousands of intracellular protein-protein interactions that remain a challenge for functional modulation by current therapeutics. In preclinical studies, Aileron’s Stapled Peptide Therapeutics have been shown to possess remarkable potency, in vivo stability and cell permeability.

**About Aileron**

Headquartered in Cambridge, Massachusetts, Aileron Therapeutics is a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptide Therapeutics. Stapled Peptides are a breakthrough solution to address thousands of therapeutically important yet currently undruggable targets. Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and modulate protein-protein interactions, critical control points for most human diseases. Founded in 2005 and supported by funding from a leading syndicate of investors, Aileron is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases. For more information: www.aileronrx.com.

**About Roche**

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

**Filing Data**

*Not available.*

**Contract**

*Not available.*

© 2009-2020, Wildwood Ventures Ltd. All rights reserved.